New hope for Hard-to-Treat cancers: experimental drug VT3989 enters human trials
NCT ID NCT04665206
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study is testing an experimental drug called VT3989, taken as a pill once a day, for people with advanced solid tumors or mesothelioma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shrink tumors or slow cancer growth. About 434 adults will participate, and the drug may be given alone or combined with other therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
M Health Fairview University of Minnesota Medical Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Monash Health
RECRUITINGClayton, Victoria, 3168, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peter MacCullum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCSF Helen Diller Family Comprehensive Cancer Center
RECRUITINGSan Francisco, California, 94158, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virginia Cancer Specialists, PC
RECRUITINGArlington, Virginia, 22201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.